Treatment options for brain metastases from melanoma

References

• de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 43(7), 3427–3433 (1983).
   PubMed Web of Science ®Google Scholar
• Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am. J. Surg. 135(6), 807–810 (1978).
   PubMed Web of Science ®Google Scholar
• Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 42(2), 660–668 (1978).
   PubMed Web of Science ®Google Scholar
• Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J. Neurooncol. 1(4), 313–317 (1983).
   PubMedGoogle Scholar
• Sze G, Shin J, Krol G, Johnson C, Liu D, Deck MD. Intraparenchymal brain metastases: MR imaging versus contrast-enhanced CT. Radiology 168(1), 187–194 (1988).
   PubMed Web of Science ®Google Scholar
• Davis PC, Hudgins PA, Peterman SB, Hoffman JC Jr. Diagnosis of cerebral metastases: double-dose delayed CT vs. contrast-enhanced MR imaging. Am. J. Neuroradiol. 12(2), 293–300 (1991).
   PubMed Web of Science ®Google Scholar
• Taphoorn MJ, Heimans JJ, Kaiser MC, de Slegte RG, Crezee FC, Valk J. Imaging of brain metastases. Comparison of computerized tomography (CT) and magnetic resonance imaging (MRI). Neuroradiology 31(5), 391–395 (1989).
   PubMedGoogle Scholar
• Einhorn LH, Burgess MA, Vallejos C et al. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res. 34(8), 1995–2004 (1974).
   PubMed Web of Science ®Google Scholar
• Budman DR, Camacho E, Wittes RE. The current causes of death in patients with malignant melanoma. Eur. J. Cancer 14(4), 327–330 (1978).
   PubMed Web of Science ®Google Scholar
• Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 37(4), 745–751 (1997).
   PubMed Web of Science ®Google Scholar
• Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 94(8), 2265–2272 (2002).
   PubMedGoogle Scholar
• Morris SL, Low SH, A’Hern RP et al. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br. J. Cancer 91(5), 829–833 (2004).
   PubMed Web of Science ®Google Scholar
• Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: a meta-analysis [see comment]. Mayo Clin. Proc. 79(12), 1489–1494 (2004).
   PubMed Web of Science ®Google Scholar
• Forsyth PA, Weaver S, Fulton D et al. Prophylactic anticonvulsants in patients with brain tumour [see comment]. Can. J. Neurol. Sci. 30(2), 106–112 (2003).
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Cole BF, Friedberg MH et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 46(4), 985–991 (1996).
   PubMed Web of Science ®Google Scholar
• Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res. 31(6), 830–833 (1971).
   PubMed Web of Science ®Google Scholar
• Carella RJ, Gelber R, Hendrickson F, Berry HC, Cooper JS. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II. Cancer 45(4), 679–683 (1980).
   PubMed Web of Science ®Google Scholar
• Stridsklev IC, Hagen S, Klepp O. Radiation therapy for brain metastases from malignant melanoma. Acta Radiol. Oncol. 23(4), 231–235 (1984).
   PubMed Web of Science ®Google Scholar
• Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer 53(11), 2550–2552 (1984).
   PubMedGoogle Scholar
• Gottlieb JA, Frei E III, Luce JK. An evaluation of the management of patients with cerebral metastases from malignant melanoma. Cancer 29(3), 701–705 (1972).
   PubMed Web of Science ®Google Scholar
• Fell DA, Leavens ME, McBride CM. Surgical versus nonsurgical management of metastatic melanoma of the brain. Neurosurgery 7(3), 238–242 (1980).
   PubMed Web of Science ®Google Scholar
• Cooper JS, Carella R. Radiotherapy of intracerebral metastatic malignant melanoma. Radiology 134(3), 735–738 (1980).
   PubMed Web of Science ®Google Scholar
• Ellerhorst J, Strom E, Nardone E, McCutcheon I. Whole brain irradiation for patients with metastatic melanoma: a review of 87 cases. Int. J. Radiat. Oncol. Biol. Phys. 49(1), 93–97 (2001).
   PubMedGoogle Scholar
• Hornsey S. The radiosensitivity of melanoma cells in culture. Br. J. Radiol. 45(530), 158 (1972).
   PubMedGoogle Scholar
• Rofstad EK. Radiation biology of malignant melanoma. Acta Radiol. Oncol. 25(1), 1–10 (1986).
   PubMedGoogle Scholar
• Hornsey S. The radiation response of human malignant melanoma cells in vitro and in vivo. Cancer Res. 32(3), 650–651 (1972).
   PubMedGoogle Scholar
• Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int. J. Radiat. Oncol. Biol. Phys. 15(4), 859–864 (1988).
   PubMed Web of Science ®Google Scholar
• Ziegler JC, Cooper JS. Brain metastases from malignant melanoma: conventional vs. high-dose-per-fraction radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 12(10), 1839–1842 (1986).
   PubMed Web of Science ®Google Scholar
• Vlock DR, Kirkwood JM, Leutzinger C, Kapp DS, Fischer JJ. High-dose fraction radiation therapy for intracranial metastases of malignant melanoma: a comparison with low-dose fraction therapy. Cancer 49(11), 2289–2294 (1982).
   PubMedGoogle Scholar
• Hagen NA, Cirrincione C, Thaler HT, DeAngelis LM. The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 40(1), 158–160 (1990).
   PubMed Web of Science ®Google Scholar
• Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J. Neurosurg. 93(1), 9–18 (2000).
   PubMed Web of Science ®Google Scholar
• Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88(1), 11–20 (1998).
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Regine WF et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial [comment]. JAMA 280(17), 1485–1489 (1998).
   PubMed Web of Science ®Google Scholar
• Zacest AC, Besser M, Stevens G, Thompson JF, McCarthy WH, Culjak G. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J. Neurosurg. 96(3), 552–558 (2002).
   PubMed Web of Science ®Google Scholar
• Konstadoulakis MM, Messaris E, Zografos G, Androulakis G, Karakousis C. Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? J. Neurosurg. Sci. 44(4), 211–219 (2000).
   PubMedGoogle Scholar
• Katz HR. The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system. Int. J. Radiat. Oncol. Biol. Phys. 7(7), 897–906 (1981).
   PubMed Web of Science ®Google Scholar
• Bremer AM, West CR, Didolkar MS. An evaluation of the surgical management of melanoma of the brain. J. Surg. Oncol. 10(3), 211–219 (1978).
   PubMedGoogle Scholar
• Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322(8), 494–500 (1990).
   PubMed Web of Science ®Google Scholar
• Noordijk EM, Vecht CJ, Haaxma-Reiche H et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age [see comment]. Int. J. Radiat. Oncol. Biol. Phys. 29(4), 711–717 (1994).
   PubMed Web of Science ®Google Scholar
• Wornom IL III, Smith JW, Soong SJ, McElvein R, Urist MM, Balch CM. Surgery as palliative treatment for distant metastases of melanoma. Ann. Surg. 204(2), 181–185 (1986).
   PubMedGoogle Scholar
• Somaza S, Kondziolka D, Lunsford LD, Kirkwood JM, Flickinger JC. Stereotactic radiosurgery for cerebral metastatic melanoma. J. Neurosurg. 79(5), 661–666 (1993).
   PubMedGoogle Scholar
• Seung SK, Shu HK, McDermott MW, Sneed PK, Larson DA. Stereotactic radiosurgery for malignant melanoma to the brain. Surg. Clin. North Am. 76(6), 1399–1411 (1996).
   PubMedGoogle Scholar
• Brown PD, Brown CA, Pollock BE, Gorman DA, Foote RL. Stereotactic radiosurgery for patients with ‘radioresistant’ brain metastases. Neurosurgery 51(3), 656–667 (2002).
   PubMedGoogle Scholar
• Selek U, Chang EL, Hassenbusch SJ III et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int. J. Radiat. Oncol. Biol. Phys. 59(4), 1097–1106 (2004).
   PubMed Web of Science ®Google Scholar
• Radbill AE, Fiveash JF, Falkenberg ET et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer 101(4), 825–833 (2004).
   PubMed Web of Science ®Google Scholar
• Mingione V, Oliveira M, Prasad D, Steiner M, Steiner L. Gamma surgery for melanoma metastases in the brain. J. Neurosurg. 96(3), 544–551 (2002).
   PubMedGoogle Scholar
• Mori Y, Kondziolka D, Flickinger JC, Kirkwood JM, Agarwala S, Lunsford LD. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int. J. Radiat. Oncol. Biol. Phys. 42(3), 581–589 (1998).
   PubMed Web of Science ®Google Scholar
• Lavine SD, Petrovich Z, Cohen-Gadol AA et al. Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery 44(1), 59–66 (1999).
   PubMedGoogle Scholar
• Grob JJ, Regis J, Laurans R et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancerologie Cutanee. Eur. J. Cancer 34(8), 1187–1192 (1998).
   PubMedGoogle Scholar
• Seung SK, Sneed PK, McDermott MW et al. Gamma knife radiosurgery for malignant melanoma brain metastases. Cancer J. Sci. Am. 4(2), 103–109 (1998).
   PubMedGoogle Scholar
• Gieger M, Wu JK, Ling MN, Wazer D, Tsai JS, Engler MJ. Response of intracranial melanoma metastases to stereotactic radiosurgery. Radiat. Oncol. Investig. 5(2), 72–80 (1997).
   PubMedGoogle Scholar
• Yu C, Chen JC, Apuzzo ML et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int. J. Radiat. Oncol. Biol. Phys. 52(5), 1277–1287 (2002).
   PubMed Web of Science ®Google Scholar
• Mañon RR ONA, Mehta M, Knisely J et al. Phase II trial of radiosurgery (RS) for 1 to 3 newly diagnosed brain metastases from renal cell, melanoma, and sarcoma: an Eastern Co-operative Oncology Group Study (E6397). Proc. Am. Soc. Clin. Oncol. (2004).
   Google Scholar
• Aoyama H SH, Nakagawa K, Tago M. Interim report of the JROSG99–1 multi-institutional randomized trial, comparing radiosurgery alone vs. radiosurgery plus whole brain irradiation for 1–4 brain metastases. Proc. Am. Soc. Clin. Oncol. (2004).
   Google Scholar
• Regine WF, Huhn JL, Patchell RA et al. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications [see comment] [erratum appears in Int. J. Radiat. Oncol. Biol. Phys. 2002 53(1), 259]. Int. J. Radiat. Oncol. Biol. Phys. 52(2), 333–338 (2002).
   Google Scholar
• Pavlick AC. Chemotherapy approaches to melanoma. Dermatol. Clin. 20(4), 709–712 (2002).
   PubMedGoogle Scholar
• Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85(7), 1599–1605 (1999).
   PubMed Web of Science ®Google Scholar
• Beretta G, Bonadonna G, Cascinelli N, Morabito A, Veronesi U. Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international co-operative study. Cancer Treat. Rep. 60(1), 33–40 (1976).
   PubMedGoogle Scholar
• Boaziz C, Breau JL, Morere JF, Israel L. Metastases cerebrales des melanomes malins. Bull. Cancer 78(4), 347–353 (1991).
   PubMedGoogle Scholar
• Kleeberg UR, Engel E, Israels P et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre Phase II trial of the EORTC-Melanoma Co-operative Group (MCG). Melanoma Res. 5(3), 195–200 (1995).
   PubMed Web of Science ®Google Scholar
• Jacquillat C, Khayat D, Banzet P et al. Final report of the French multicenter Phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66(9), 1873–1878 (1990).
   PubMed Web of Science ®Google Scholar
• Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N. Engl. J. Med. 345(8), 621–622 (2001).
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 18(1), 158–166 (2000).
   PubMed Web of Science ®Google Scholar
• Bleehen NM, Newlands ES, Lee SM et al. Cancer Res.earch Campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol. 13(4), 910–913 (1995).
   Google Scholar
• Bafaloukos D, Tsoutsos D, Fountzilas G et al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res. 14(4), 289–294 (2004).
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Kirkwood JM, Gore M et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a Phase II study. J. Clin. Oncol. 22(11), 2101–2107 (2004).
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Krown SE, Menell JH et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol. 21(17), 3351–3356 (2003).
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Raizer J, Panageas KS, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol. 2(10), 634–635 (2001).
   PubMed Web of Science ®Google Scholar
• Hwu WJKS, Lis E, Menell JH et al. Phase II study of temozolomide (TMZ) plus thalidomide in patients with brain metastasis from malignant melanoma. Proc. Am. Soc. Clin. Oncol. (2003).
   Google Scholar
• Mornex F, Thomas L, Mohr P et al. Essai de Phase III randomise comparant la fotemustine seule ou associee a une irradiation encephalique dans les metastases cerebrales de melanome. Cancer Radiother. 7(1), 1–8 (2003).
   PubMedGoogle Scholar
• Dardoufas CMA, Skarleas C, Kouloulias V et al. Concomitant temozolomide (TMZ) and radiotherapy (RT) followed by adjuvant treatment with temozolomide in patients with brain metastases from solid tumours. Proc. Am. Soc. Clin. Oncol. (2001).
   Google Scholar
• Margolin K, Atkins B, Thompson A et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a Phase II trial of the Cytokine Working Group. J. Cancer Res. Clin. Oncol. 128(4), 214–218 (2002).
   PubMed Web of Science ®Google Scholar
• Atkins MBSJ, Agarwala S, Logan T et al. A Cytokine Working Group Phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma. Proc. Am. Soc. Clin. Oncol. (2005).
   Google Scholar
• Guirguis LM, Yang JC, White DE et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J. Immunother. 25(1), 82–87 (2002).
   PubMedGoogle Scholar
• Spitler LE, Wong P, Sagebiel R. Combined immunotherapy of malignant melanoma. Unusual survival following cerebral metastasis. Archives of Dermatology 114(10), 1501–1504 (1978).
   Google Scholar
• Savas B, Arslan G, Gelen T, Karpuzoglu G, Ozkaynak C. Multi-drug resistant malignant melanoma with intracranial metastasis responding to immunotherapy. Anticancer Res. 19(5C), 4413–4420 (1999).
   PubMed Web of Science ®Google Scholar
• Boasberg PD, O’Day SJ, Kristedja TS et al. Biochemotherapy for metastatic melanoma with limited central nervous system involvement. Oncology 64(4), 328–335 (2003).
   PubMed Web of Science ®Google Scholar
• Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J. Clin. Oncol. 12(3), 627–642 (1994).
   PubMed Web of Science ®Google Scholar